What is the nature of Robert C. Malenka’s indirect MPLT share holdings?

The indirect holdings relate to 31,672 shares in the Robert C. Malenka Living Trust. A footnote notes he is the trust’s sole trustee and holds voting and dispositive power over those shares, meaning he controls how they are voted and potentially sold.

MapLight (MPLT) director sells 8,593 shares under 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics director Robert C. Malenka sold 8,593 shares of Voting Common Stock on April 15, 2026 in an open-market transaction at a weighted average price of $26.90 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.

After the sale, Malenka held 316,466 shares directly, and a separate filing line shows 31,672 shares held indirectly through the Robert C. Malenka Living Trust, where he is sole trustee with voting and dispositive power. The reported sales occurred in multiple trades between $26.35 and $27.29 per share.

Insider Trade Summary 10b5-1

Net Seller: 8,593 shares ($231,152)

Net Sell 2 txns

Insider Malenka Robert C.

Role Director

Sold 8,593 shs ($231K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	8,593	$26.90	$231K
holding	Voting Common Stock	--	--	--

Holdings After Transaction: Voting Common Stock — 316,466 shares (Direct); Voting Common Stock — 31,672 shares (Indirect, See footnote)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

Key Figures

Shares sold: 8,593 shares Weighted average sale price: $26.90 per share Post-transaction direct holdings: 316,466 shares +3 more

6 metrics

Shares sold 8,593 shares Open-market sale on April 15, 2026

Weighted average sale price $26.90 per share Voting Common Stock sale on April 15, 2026

Post-transaction direct holdings 316,466 shares Voting Common Stock held directly after sale

Indirect trust holdings 31,672 shares Robert C. Malenka Living Trust position

Trade price range $26.35–$27.29 per share Range of individual sale prices on April 15, 2026

10b5-1 plan adoption date December 26, 2025 Pre-arranged trading plan governing the sale

Key Terms

Rule 10b5-1 trading plan, weighted average sales price, Voting Common Stock, living trust

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"The price reported is a weighted average sales price."

Voting Common Stock financial

"security_title": "Voting Common Stock""

living trust financial

"The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee"

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malenka Robert C.

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	04/15/2026		S⁽¹⁾		8,593	D	$26.9⁽²⁾	316,466	D
Voting Common Stock								31,672	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MPLT director Robert C. Malenka report?

Director Robert C. Malenka reported selling 8,593 shares of MapLight Therapeutics Voting Common Stock. The sale occurred on April 15, 2026 as an open-market transaction, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.

At what price did Robert C. Malenka sell MPLT shares?

Malenka’s sale used a weighted average price of $26.90 per share. Footnotes state the 8,593 shares were sold in multiple transactions, with individual trade prices ranging from $26.35 to $27.29 per share during the April 15, 2026 trading session.

How many MPLT shares does Robert C. Malenka hold after this sale?

Following the reported sale, Malenka directly held 316,466 shares of MapLight Therapeutics Voting Common Stock. A separate line also shows 31,672 shares held indirectly through his living trust, where he serves as sole trustee with full voting and dispositive power.

Was the MPLT insider sale by Robert C. Malenka pre-planned?

Yes. A footnote explains the transaction was carried out under a Rule 10b5-1 trading plan. That plan was adopted on December 26, 2025, indicating the sales were scheduled in advance rather than initiated discretionarily on the trade date.